Journal
CARCINOGENESIS
Volume 39, Issue 7, Pages 931-936Publisher
OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgy052
Keywords
-
Categories
Funding
- National Institutes of Health, USA [R01CA197903, R01CA164509]
- National Science Foundation, USA [CHE1213161]
- National Natural Science Foundation of China, China [cstc2016shms-ztzx10003, NSFC81270569]
- NATIONAL CANCER INSTITUTE [R01CA164509, R01CA197903] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [T90DE021982] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Glioblastoma multiforme (GBM) remains an incurable brain tumor. The highly malignant behavior of GBM may, in part, be attributed to its intraclonal genetic and phenotypic diversity (subclonal evolution). Identifying the molecular pathways driving GBM relapse may provide novel, actionable targets for personalized diagnosis, characterization of prognosis and improvement of precision therapy. We screened single-cell transcriptomes, namely RNA-seq data of primary and relapsed GBM tumors from a patient, to define the molecular profile of relapse. Characterization of hundreds of individual tumor cells identified three mutated genes within single cells, involved in the RAS/GEF GTP-dependent signaling pathway. The identified molecular pathway was further verified by meta-analysis of RNA-seq data from more than 3000 patients. This study showed that single-cell molecular analysis overcomes the inherent heterogeneity of bulk tumors with respect to defining tumor subclonal evolution relevant to GBM relapse.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available